Clinical trials: MG - Myasthenia Gravis
Myasthenia Gravis
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
Primary study objective: To confirm the efficacy of HBM9161 subcutaneous injection for the treatment of gMG in Chinese patients
- Trial name
- MG (NCT05039190)
- Testing
- HBM9161 Injection (680mg)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Generalized Myasthenia Gravis
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
- Trial name
- RELIEVE (NCT06744920)
- Testing
- Remibrutinib (Blinded), Remibrutinib (Open Label)
- Where
- 120 sites in United States, Argentina and 18 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Acute Inflammatory Demyelinating Polyradiculoneuropathy, Myasthenia Gravis
Perception and Multisensory Integration in Neurological Patients Using fMRI
The main objective of the study is to explore and map brain areas involved in sensory perception and multisensory integration in patients with central or peripheral neurological damage.
- Conditions
- Acute Inflammatory Demyelinating Polyradiculoneuropathy, Myasthenia Gravis, Stroke, Anosognosia
- Trial name
- NCT01469858
- Testing
- Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Myasthenia Gravis
Cognitive Functioning in People With Myasthenia Graivs: Impact on Daily Life Activities, Work, Disability and Quality of Life
MYCOG primarily aims to estimate the prevalence of cognitive difficulties in patients with MG treated at Besta Institute. Secondary aims include: a) assess the degree to which cognitive difficulties are associated to work…
- Trial name
- MYCOG (NCT06718855)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Myasthenia Gravis
Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia Gravis
Ocular muscle myasthenia gravis (Ocular Myasthenia Gravis, OMG) has a high incidence and is difficult to diagnose. It is very necessary to find specific diagnostic indicators for OMG.
- Trial name
- NCT05888558
- Testing
- Body fluid diagnosis
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Jinan University
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of…
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
- Trial name
- NCT06312644
- Testing
- Ultomiris
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myasthenia Gravis
A Prospective Cohort Study of Myasthenia Gravis in China
The goal of this prospective cohort study is to investigate long-term therapeutic strategies for myasthenia gravis (MG) and identify potential biomarkers. The main questions it aims to answer are: 1.
- Trial name
- NCT06006832
- Testing
- Steroid Drug, Withdraw all immunosuppresants
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Peking Union Medical College Hospital
Generalized Myasthenia Gravis
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG.
- Trial name
- ADAPT Jr (NCT04833894)
- Testing
- Efgartigimod IV
- Where
- 25 sites in United States, Austria and 10 more
- Volunteers
- 15 people
- Sponsor
- argenx
Generalized Myasthenia Gravis, gMG
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
- Trial name
- NCT05644561
- Testing
- Ravulizumab
- Where
- 11 sites in United States, Italy and 3 more
- Volunteers
- 12 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.
- Trial name
- NCT06471361
- Testing
- Zilucoplan
- Where
- 11 sites in United States, Poland and 1 more
- Volunteers
- 31 people
- Sponsor
- UCB Biopharma SRL
Myositis, Myasthenia Gravis
Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
The traditional treatment of inflammatory myopathies (IM) and generalized myasthenia gravis (MG) is immunosuppressive therapy, usually beginning with corticosteroids.
- Trial name
- FORCE (NCT00774462)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).
- Trial name
- LEMS (NCT00872950)
- Testing
- 3,4-DIAMINOPYRIDINE
- Where
- United States
- Sponsor
- Lahey Clinic
Cystic Fibrosis, Hemophilia A
Medication Adherence and Non-adherence in Adults With Rare Disease
The purpose of this study is to use the Medication Adherence Reasons Scale (MAR-Scale) to determine the extent of non-adherence to specific medications indicated to treat cystic fibrosis, hemophilia (A or B), idiopathic pulmonary…
- Conditions
- Cystic Fibrosis, Hemophilia A, Hemophilia B, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT04541875
- Testing
- MAR-Scale
- Volunteers
- healthy volunteers welcome
- Sponsor
- Xperiome
Generalized Myasthenia Gravis
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NCT03315130
- Testing
- zilucoplan (RA101495)
- Where
- 30 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Ra Pharmaceuticals
Generalized Myasthenia Gravis
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
- Trial name
- NCT04124965
- Testing
- Rozanolixizumab
- Where
- 43 sites in United States, Canada and 10 more
- Volunteers
- 71 people
- Sponsor
- UCB Biopharma SRL
Myasthenia Gravis
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in…
- Trial name
- NCT02473965
- Testing
- IGIV-C
- Where
- 39 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Grifols Therapeutics LLC
Myasthenia Gravis (MG)
Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis
Through a retrospective cohort study method, the influence of Gu-Lu Er-Xian Decoction with modified formula on the long-term therapeutic effect of patients with myasthenia gravis was analyzed, and the related factors affecting…
- Trial name
- NCT07472777
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Beijing University of Chinese Medicine
Lambert Eaton Myasthenic Syndrome
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
- Trial name
- 3 4-DAP (NCT01825395)
- Testing
- 3, 4-Diaminopyridine
- Where
- United States
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis (MS), Myasthenia Gravis (MG)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus
- Trial name
- NCT07676266
- Testing
- CD20/BCMA-directed CAR-T cells Autologous 2nd generation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Lambert Eaton Myasthenic Syndrome
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
- Trial name
- NCT01377922
- Testing
- Amifampridine Phosphate
- Where
- 14 sites in United States, France and 6 more
- Volunteers
- 38 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.